Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.
Drugs
Health
Pharma
Drugs
Health
Pharma
FDA gives nod to Bristol Myer’s colorectal cancer therapy
The US Food and Drug Administration has greenlighted Bristol Myers Squibb’s combination therapy to treat metastatic colorectal cancer in patients with a mutated.